Wearable sensors and AI to spot chest infection flare-ups in cystic fibrosis and bronchiectasis
Studies body sensors during chest infection treatment in adults with cystic fibrosis or bronchiectasis.
Key facts
- Who runs it
- Papworth Hospital NHS Foundation Trust
- Where
- Cambridge, United KingdomSee the site
- Trial code
- Registry title
- Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchiectasis
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 30 Sept 2025
- Planned end
- 30 Apr 2026
- Type of study
- Observational
- Treatments tested
- Non-Interventional Study
- Record updated
- 17 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cystic fibrosis or bronchiectasis who are starting intravenous antibiotics for a flare-up of their lung disease. It is an observational study that tests sensors.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Cystic fibrosis confirmed by genetic testing and/or sweat chloride levels, or non-CF bronchiectasis confirmed by CT. They must be starting IV antibiotics for an acute pulmonary exacerbation (APE) as defined by the Hill Criteria.
Main reasons for not taking part
- Cannot give written informed consent
- Lung transplant recipient or on the lung transplant waiting list
- Uses long-term oxygen therapy or non-invasive ventilation for respiratory failure
- Does not agree to anonymised home monitoring data being used for research
- Admitted for planned (elective) antibiotic treatment, not for an acute flare-up
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- ≥ 18 years old
- Diagnosis of CF based on genetic testing and /or sweat chloride levels or CT confirmed diagnosis of non-CF bronchiectasis
- Under the care of Royal Papworth Hospital
- Starting IV antibiotics for treatment of APE as defined by the Hill Criteria ²
Who cannot take part
- Lung transplant recipients or on lung transplant waiting list
- Use of long-term oxygen therapy (LTOT) or non-invasive ventilation to manage respiratory failure
- Patients unable to provide written informed consent
- Patients unwilling to consent to their link anonymised data from home monitoring being used for research
- Considered unsuitable for home monitoring in the opinion of the investigator
- Patients being admitted for elective antibiotic treatment (i.e. not being admitted for acute APE treatment)
Where in United Kingdom
- Royal Papworth Hospital NHS Foundation TrustCambridge, United KingdomContact: Lucy E GaleTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to learn about new sensors that measure changes in the body that happen during a chest infection, such as breathing rate and heart rate. This study will be with adults who have either cystic fibrosis or bronchiectasis who start treatment with intravenous antibiotics (usually for around 2 weeks).
Read full original descriptionShow less
The main question it aims to answer is the change in sensor measure (such as heart rate) between the start and end of treatment for a chest infection.
No follow up visits are required for this study.
Treatments tested
- Non-Interventional Study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis
- Plain-language title
- Wearable sensors and AI to spot chest infection flare-ups in cystic fibrosis and bronchiectasisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 December 2025